Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer

A pilot study

Elisabeth Weiss, John Ford, Kathryn M. Olsen, Kishor Karki, Siddharth Saraiya, Robert Groves, Geoffrey D. Hugo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objectives: Serial diffusion-weighted magnetic resonance imaging (DW-MRI) during radiochemotherapy of non-small cell lung cancer (NSCLC) is analyzed to investigate the apparent diffusion coefficient (ADC) as a potential biomarker for tumor response. Methods: Ten patients underwent DW-MRI prior to and at three and six weeks during radiochemotherapy. Three methods of contouring primary tumors (PT) were performed to evaluate the impact of tumor heterogeneity on ADC values: PTT: whole tumor volume; PTT-N: PTT-necrosis; PTL: small volume of presumed active tumor with low ADC value. Pretreatment and during-treatment absolute ADC values and ADC value changes were analyzed for PT and involved lymph nodes (LN). Results: ADC values for PTT, PTT-N, PTL and LN increased by 8-14% (PT) and 15% (LN) at three weeks, and 19-26% and 23% at 6 weeks post initial treatment (p = 0.04-0.002). Average percent ADC value increase was smaller than tumor volume regression (p = 0.06-0.0005). Patients with overall survival T). Conclusions: Significant ADC value increases during radiochemotherapy for non-small cell lung cancer were observed. ADC value change during treatment appears to be an independent marker of patient outcome and warrants further investigation.

Original languageEnglish (US)
Pages (from-to)113-119
Number of pages7
JournalLung Cancer
Volume96
DOIs
StatePublished - Jun 1 2016

Fingerprint

Diffusion Magnetic Resonance Imaging
Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Lymph Nodes
Neoplasms
Tumor Burden
Tumor Biomarkers
Necrosis
Therapeutics
Survival

Keywords

  • Diffusion-weighted MRI
  • Non small cell lung cancer
  • Radiotherapy
  • Response assessment

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer : A pilot study. / Weiss, Elisabeth; Ford, John; Olsen, Kathryn M.; Karki, Kishor; Saraiya, Siddharth; Groves, Robert; Hugo, Geoffrey D.

In: Lung Cancer, Vol. 96, 01.06.2016, p. 113-119.

Research output: Contribution to journalArticle

Weiss, Elisabeth ; Ford, John ; Olsen, Kathryn M. ; Karki, Kishor ; Saraiya, Siddharth ; Groves, Robert ; Hugo, Geoffrey D. / Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer : A pilot study. In: Lung Cancer. 2016 ; Vol. 96. pp. 113-119.
@article{81291922997e45f2b589e2fb7a6da458,
title = "Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer: A pilot study",
abstract = "Objectives: Serial diffusion-weighted magnetic resonance imaging (DW-MRI) during radiochemotherapy of non-small cell lung cancer (NSCLC) is analyzed to investigate the apparent diffusion coefficient (ADC) as a potential biomarker for tumor response. Methods: Ten patients underwent DW-MRI prior to and at three and six weeks during radiochemotherapy. Three methods of contouring primary tumors (PT) were performed to evaluate the impact of tumor heterogeneity on ADC values: PTT: whole tumor volume; PTT-N: PTT-necrosis; PTL: small volume of presumed active tumor with low ADC value. Pretreatment and during-treatment absolute ADC values and ADC value changes were analyzed for PT and involved lymph nodes (LN). Results: ADC values for PTT, PTT-N, PTL and LN increased by 8-14{\%} (PT) and 15{\%} (LN) at three weeks, and 19-26{\%} and 23{\%} at 6 weeks post initial treatment (p = 0.04-0.002). Average percent ADC value increase was smaller than tumor volume regression (p = 0.06-0.0005). Patients with overall survival T). Conclusions: Significant ADC value increases during radiochemotherapy for non-small cell lung cancer were observed. ADC value change during treatment appears to be an independent marker of patient outcome and warrants further investigation.",
keywords = "Diffusion-weighted MRI, Non small cell lung cancer, Radiotherapy, Response assessment",
author = "Elisabeth Weiss and John Ford and Olsen, {Kathryn M.} and Kishor Karki and Siddharth Saraiya and Robert Groves and Hugo, {Geoffrey D.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2016.04.001",
language = "English (US)",
volume = "96",
pages = "113--119",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer

T2 - A pilot study

AU - Weiss, Elisabeth

AU - Ford, John

AU - Olsen, Kathryn M.

AU - Karki, Kishor

AU - Saraiya, Siddharth

AU - Groves, Robert

AU - Hugo, Geoffrey D.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Objectives: Serial diffusion-weighted magnetic resonance imaging (DW-MRI) during radiochemotherapy of non-small cell lung cancer (NSCLC) is analyzed to investigate the apparent diffusion coefficient (ADC) as a potential biomarker for tumor response. Methods: Ten patients underwent DW-MRI prior to and at three and six weeks during radiochemotherapy. Three methods of contouring primary tumors (PT) were performed to evaluate the impact of tumor heterogeneity on ADC values: PTT: whole tumor volume; PTT-N: PTT-necrosis; PTL: small volume of presumed active tumor with low ADC value. Pretreatment and during-treatment absolute ADC values and ADC value changes were analyzed for PT and involved lymph nodes (LN). Results: ADC values for PTT, PTT-N, PTL and LN increased by 8-14% (PT) and 15% (LN) at three weeks, and 19-26% and 23% at 6 weeks post initial treatment (p = 0.04-0.002). Average percent ADC value increase was smaller than tumor volume regression (p = 0.06-0.0005). Patients with overall survival T). Conclusions: Significant ADC value increases during radiochemotherapy for non-small cell lung cancer were observed. ADC value change during treatment appears to be an independent marker of patient outcome and warrants further investigation.

AB - Objectives: Serial diffusion-weighted magnetic resonance imaging (DW-MRI) during radiochemotherapy of non-small cell lung cancer (NSCLC) is analyzed to investigate the apparent diffusion coefficient (ADC) as a potential biomarker for tumor response. Methods: Ten patients underwent DW-MRI prior to and at three and six weeks during radiochemotherapy. Three methods of contouring primary tumors (PT) were performed to evaluate the impact of tumor heterogeneity on ADC values: PTT: whole tumor volume; PTT-N: PTT-necrosis; PTL: small volume of presumed active tumor with low ADC value. Pretreatment and during-treatment absolute ADC values and ADC value changes were analyzed for PT and involved lymph nodes (LN). Results: ADC values for PTT, PTT-N, PTL and LN increased by 8-14% (PT) and 15% (LN) at three weeks, and 19-26% and 23% at 6 weeks post initial treatment (p = 0.04-0.002). Average percent ADC value increase was smaller than tumor volume regression (p = 0.06-0.0005). Patients with overall survival T). Conclusions: Significant ADC value increases during radiochemotherapy for non-small cell lung cancer were observed. ADC value change during treatment appears to be an independent marker of patient outcome and warrants further investigation.

KW - Diffusion-weighted MRI

KW - Non small cell lung cancer

KW - Radiotherapy

KW - Response assessment

UR - http://www.scopus.com/inward/record.url?scp=84962809943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962809943&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2016.04.001

DO - 10.1016/j.lungcan.2016.04.001

M3 - Article

VL - 96

SP - 113

EP - 119

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -